Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

CD44 and OTP are strong prognostic markers for pulmonary carcinoids.

Swarts DR, Henfling ME, Van Neste L, van Suylen RJ, Dingemans AM, Dinjens WN, Haesevoets A, Rudelius M, Thunnissen E, Volante M, Van Criekinge W, van Engeland M, Ramaekers FC, Speel EJ.

Clin Cancer Res. 2013 Apr 15;19(8):2197-207. doi: 10.1158/1078-0432.CCR-12-3078. Epub 2013 Feb 26.

2.

Prognostic Significance of CD44 and Orthopedia Homeobox Protein (OTP) Expression in Pulmonary Carcinoid Tumours.

Papaxoinis G, Nonaka D, O'Brien C, Sanderson B, Krysiak P, Mansoor W.

Endocr Pathol. 2017 Mar;28(1):60-70. doi: 10.1007/s12022-016-9459-y.

PMID:
27873160
3.

An exploration of pathways involved in lung carcinoid progression using gene expression profiling.

Swarts DR, Van Neste L, Henfling ME, Eijkenboom I, Eijk PP, van Velthuysen ML, Vink A, Volante M, Ylstra B, Van Criekinge W, van Engeland M, Ramaekers FC, Speel EJ.

Carcinogenesis. 2013 Dec;34(12):2726-37. doi: 10.1093/carcin/bgt271. Epub 2013 Aug 8.

4.

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.

Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

Breast Cancer Res Treat. 2010 Jul;122(2):315-24. doi: 10.1007/s10549-009-0568-x. Epub 2009 Oct 1.

PMID:
19795205
5.

Interobserver variability for the WHO classification of pulmonary carcinoids.

Swarts DR, van Suylen RJ, den Bakker MA, van Oosterhout MF, Thunnissen FB, Volante M, Dingemans AM, Scheltinga MR, Bootsma GP, Pouwels HM, van den Borne BE, Ramaekers FC, Speel EJ.

Am J Surg Pathol. 2014 Oct;38(10):1429-36. doi: 10.1097/PAS.0000000000000300.

PMID:
25046341
6.

MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids.

Swarts DR, Scarpa A, Corbo V, Van Criekinge W, van Engeland M, Gatti G, Henfling ME, Papotti M, Perren A, Ramaekers FC, Speel EJ, Volante M.

J Clin Endocrinol Metab. 2014 Feb;99(2):E374-8. doi: 10.1210/jc.2013-2782. Epub 2013 Nov 25.

7.

Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.

Laitinen KL, Soini Y, Mattila J, Pääkkö P.

Cancer. 2000 Apr 1;88(7):1590-8.

PMID:
10738217
8.

Diagnostic Utility of Orthopedia Homeobox (OTP) in Pulmonary Carcinoid Tumors.

Nonaka D, Papaxoinis G, Mansoor W.

Am J Surg Pathol. 2016 Jun;40(6):738-44. doi: 10.1097/PAS.0000000000000621.

PMID:
26927888
9.

Promyelocytic leukemia zinc finger and histone H1.5 differentially stain low- and high-grade pulmonary neuroendocrine tumors: a pilot immunohistochemical study.

Hechtman JF, Beasley MB, Kinoshita Y, Ko HM, Hao K, Burstein DE.

Hum Pathol. 2013 Jul;44(7):1400-5. doi: 10.1016/j.humpath.2012.11.014. Epub 2013 Feb 14.

PMID:
23416030
10.

Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.

Pelosi G, Scarpa A, Puppa G, Veronesi G, Spaggiari L, Pasini F, Maisonneuve P, Iannucci A, Arrigoni G, Viale G.

Cancer. 2005 Mar 15;103(6):1154-64.

11.

Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors.

Kovatich A, Friedland DM, Druck T, Hadaczek P, Huebner K, Comis RL, Hauck W, McCue PA.

Cancer. 1998 Sep 15;83(6):1109-17.

PMID:
9740075
12.

CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.

Nguyen VN, Mirejovský T, Melinová L, Mandys V.

Neoplasma. 2000;47(6):400-8.

PMID:
11263866
13.

Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.

Berner HS, Suo Z, Risberg B, Villman K, Karlsson MG, Nesland JM.

Histopathology. 2003 Jun;42(6):546-54.

PMID:
12786890
14.

Alterations in the expression of p53, KLF4, and p21 in neuroendocrine lung tumors.

Naranjo Gómez JM, Bernal JF, Arranz PG, Fernández SL, Roman JJ.

Arch Pathol Lab Med. 2014 Jul;138(7):936-42. doi: 10.5858/arpa.2013-0119-OA.

PMID:
24978920
15.

Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors.

Igarashi T, Jiang SX, Kameya T, Asamura H, Sato Y, Nagai K, Okayasu I.

Mod Pathol. 2004 Oct;17(10):1259-67.

16.

CD44 expression indicates favorable prognosis in epithelial ovarian cancer.

Sillanpää S, Anttila MA, Voutilainen K, Tammi RH, Tammi MI, Saarikoski SV, Kosma VM.

Clin Cancer Res. 2003 Nov 1;9(14):5318-24.

17.

Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.

Coppola D, Clarke M, Landreneau R, Weyant RJ, Cooper D, Yousem SA.

Mod Pathol. 1996 May;9(5):484-90.

PMID:
8733762
18.

First report on metastasizing small bowel carcinoids in first-degree relatives in three generations.

Järhult J, Landerholm K, Falkmer S, Nordenskjöld M, Sundler F, Wierup N.

Neuroendocrinology. 2010;91(4):318-23. doi: 10.1159/000299790. Epub 2010 May 12.

PMID:
20460879
19.

Infrequent mutations of the p53 gene in pulmonary carcinoid tumors.

Lohmann DR, Fesseler B, Pütz B, Reich U, Böhm J, Präuer H, Wünsch PH, Höfler H.

Cancer Res. 1993 Dec 1;53(23):5797-801.

20.

Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids.

Pelosi G, Pasini F, Fraggetta F, Pastorino U, Iannucci A, Maisonneuve P, Arrigoni G, De Manzoni G, Bresaola E, Viale G.

Lung Cancer. 2003 Nov;42(2):203-13.

PMID:
14568688

Supplemental Content

Support Center